The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment.
Athanasios Kotsakis
No relevant relationships to disclose
Nikolaos K. Kentepozidis
No relevant relationships to disclose
Ioannis I. Varthalitis
No relevant relationships to disclose
Vasilios Karavasilis
No relevant relationships to disclose
Epaminontas Samantas
No relevant relationships to disclose
Charalampos Christophyllakis
No relevant relationships to disclose
Eleftheria- Kleio Dermitzaki
No relevant relationships to disclose
Nikolaos Ziras
No relevant relationships to disclose
Sofia Agelaki
No relevant relationships to disclose
Haralambos P. Kalofonos
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Research Funding - Sanofi